Bayer looks to expand Kerendia label to include heart failure

Bayer has added three investigator-sponsored Phase III clinical trials evaluating Kerendia (finerenone) for the treatment of heart failure.

Kerendia is one of Bayer’s best-selling drugs, with reported sales of €67m ($72.6m) in Q2 2023, as per the company’s half-year report. GlobalData expects the sales to grow up to $1.4bn in 2029.